Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of Measuring Genetic Polymorphisms in Metabolizing Enzymes of Tacrolimus within One Medical Facility.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi - 1 Jan 2017

Kaneko Tomohiro, Arai Momoko, Watanabe Atsushi, Tsuruoka Shuichi

Abstract excerpt

OBJECTIVES: Because genetic polymorphisms cause diverse activity in drug metabolizing enzymes, drug concentrations in the blood may be variable among patients. We analyzed the genotypes of CYP3A5 and MDR1, and investigated their relationship with whole blood drug concentrations. METHODS: Eight patients were administered an oral dose of tacrolimus for one week or longer prior to enrollment in this study. Whole...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Autoimmune Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Immunosuppressive Agents

Share to Polymorphism, Genetic

Share to Precision Medicine

Share to Tacrolimus

Share to Young Adult

Source

Identifiers

PMID: 29279557
DOI: 10.1272/jnms.84.274

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of Measuring Genetic Polymorphisms in Metabolizing Enzymes of Tacrolimus within One Medical Facility.PMID 29279557Read ↗

Genetic polymorphisms and individualized tacrolimus dosing.Semantic proximity Read ↗

CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole.Semantic proximity Read ↗

Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype.Semantic proximity Read ↗

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.Semantic proximity Read ↗

CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients.Semantic proximity Read ↗

Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.Semantic proximity Read ↗

Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.Semantic proximity Read ↗

Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.Semantic proximity Read ↗

Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation.Semantic proximity Read ↗

Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.Semantic proximity Read ↗

Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients.Semantic proximity Read ↗

Use of pharmacogenetics to optimize immunosuppressive therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.